Silence Therapeutics (NASDAQ:SLN) Stock Price Down 2.5%

Shares of Silence Therapeutics plc (NASDAQ:SLN) traded down 2.5% during mid-day trading on Friday . The stock traded as low as $20.40 and last traded at $20.65. 64,577 shares changed hands during trading, a decline of 68% from the average session volume of 201,927 shares. The stock had previously closed at $21.17.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Thursday, June 27th. Chardan Capital raised their price objective on Silence Therapeutics from $42.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, June 28th. Finally, Morgan Stanley raised their price objective on Silence Therapeutics from $45.00 to $49.00 and gave the stock an “overweight” rating in a report on Friday, June 28th.

Silence Therapeutics Stock Down 2.7 %

The stock has a market cap of $616.56 million, a price-to-earnings ratio of -17.62 and a beta of 1.30. The stock has a fifty day moving average of $20.62 and a two-hundred day moving average of $21.12.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Thursday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.18. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. The firm had revenue of $15.73 million for the quarter, compared to analysts’ expectations of $4.53 million. Equities research analysts anticipate that Silence Therapeutics plc will post -1.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC lifted its stake in shares of Silence Therapeutics by 10.5% during the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after purchasing an additional 667 shares in the last quarter. Parkman Healthcare Partners LLC increased its position in shares of Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after acquiring an additional 40,063 shares during the last quarter. Lynx1 Capital Management LP increased its position in shares of Silence Therapeutics by 123.4% during the first quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock worth $11,375,000 after acquiring an additional 290,855 shares during the last quarter. Vivo Capital LLC purchased a new stake in shares of Silence Therapeutics during the fourth quarter worth about $8,862,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of Silence Therapeutics during the first quarter worth about $13,575,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.